Thymosin Beta-4

Overview

What is Thymosin Beta-4?

Thymosin Beta-4 (Tβ4) is a naturally occurring 43-amino acid peptide that plays a crucial role in tissue repair, wound healing, and cellular regeneration. It promotes angiogenesis, reduces inflammation, and supports the migration and differentiation of various cell types involved in healing processes.

Key Benefits

Systemic regenerative effects, proven clinical efficacy, optimal bioavailability for tissue repair

Mechanism of Action

Direct systemic delivery provides optimal bioavailability and distribution to target tissues for comprehensive regenerative effects

Research Indications

Tissue Repair Most Effective

Wound Healing Acceleration

Clinical trials show 67% complete healing vs 25% placebo in pressure ulcers

Post-Surgical Recovery

Enhanced tissue regeneration and reduced healing time in surgical wounds

Soft Tissue Injury Repair

Accelerated recovery in muscle, tendon, and ligament injuries

Cardiovascular Effective

Cardiac Protection Post-MI

Phase 2b trials show 43% reduction in infarct size when given within 6 hours

Coronary Artery Disease

Improved cardiac function and reduced adverse remodeling

Peripheral Vascular Disease

Enhanced angiogenesis and improved blood flow to affected tissues

Neuroprotection Moderate

Stroke Recovery Enhancement

Improved neurological outcomes and functional recovery in animal models

Traumatic Brain Injury

Reduced brain edema and enhanced neural repair mechanisms

Spinal Cord Injury Support

Neuroprotective effects and functional recovery promotion

Research Protocols

Disclaimer

These are commonly discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified healthcare provider.

Goal	Dose	Frequency	Route
Acute Wound Healing	1.6 mg	Daily	SubQ
Cardiac Protection	42 mg	Single dose	IV bolus within 6 hours of MI
Chronic Tissue Repair	6 mg	Twice weekly	SubQ
Neurological Recovery	30 mg	Three times over 72 hours	IV infusion
General Regeneration	2-5 mg	Daily or every other day	SubQ
Research Protocol	0.6-14 mg	As per study design	SubQ or IV as indicated

Timing

Most effective when started early in the injury/healing process. For cardiac protection, must be given within 6 hours of symptom onset. Can be administered any time of day for chronic conditions.

Peptide Interactions

TB-500 Synergistic

TB-500 is the bioactive fragment of Thymosin β4. Combined use provides full-length peptide benefits plus concentrated bioactive effects for enhanced tissue repair.

BPC-157 Synergistic

Complementary healing mechanisms - Tβ4 promotes cell migration and angiogenesis while BPC-157 enhances gastric protection and systemic healing.

Growth Hormone Compatible

No direct interactions reported. Both promote tissue repair through different pathways and can be used together safely.

IGF-1 Compatible

Complementary growth factor effects without direct interaction. Both support tissue regeneration through distinct mechanisms.

Corticosteroids Use Caution

Steroids may reduce Thymosin β4 effectiveness by inhibiting inflammatory responses necessary for optimal healing.

Anticoagulants Monitor Combination

Tβ4 promotes angiogenesis which may affect bleeding risk. Monitor coagulation parameters when used with warfarin or similar agents.

NSAIDs Requires Timing

High-dose NSAIDs may interfere with inflammatory processes necessary for Tβ4-mediated healing. Consider timing or reduced NSAID dosing.

Chemotherapy Avoid Combination

Theoretical concern about promoting angiogenesis in cancer patients. Avoid use during active chemotherapy treatment.

How to Reconstitute

Important

Always use bacteriostatic water (BAC). Sterile technique is essential.

1
Allow lyophilized powder to reach room temperature before reconstitution
2
Add bacteriostatic water slowly to the vial wall, avoiding direct contact with powder
3
Gently swirl (do not shake vigorously) until completely dissolved
4
Inspect solution for clarity - should be clear and colorless
5
Store reconstituted solution at 2-8°C and use within 14 days
6
For injection, use proper aseptic technique and rotate injection sites

Quality Indicators

✓

Clear, colorless solution

Reconstituted Thymosin β4 should be clear and colorless without particles
✓

Proper sterile packaging

Lyophilized powder in sterile vials with intact seals and labeling
✓

Certificate of analysis

Third-party testing showing >98% purity and endotoxin levels <10 EU/mg
✓

Appropriate molecular weight

HPLC/MS confirmation of 4,921 Da molecular weight for 43-amino acid sequence
X

Cloudy or discolored solution

Any turbidity or color change indicates degradation or contamination
X

Crystallization after reconstitution

Visible crystals suggest improper storage or expired product
!

Room temperature storage claims

Legitimate Thymosin β4 requires refrigeration after reconstitution

What to Expect

Week 1-2: Initial tissue response, possible mild injection site reactions
Week 2-4: Accelerated healing becomes apparent, reduced inflammation
Week 4-8: Significant tissue regeneration and functional improvement
Week 8-12: Sustained benefits and near-complete healing in responsive conditions

Side Effects & Safety

Monitor injection sites for local reactions or inflammation
Use sterile technique to prevent infection at injection sites
Start with lower doses to assess individual tolerance
Discontinue if signs of allergic reaction or unusual side effects

Severe injection site reactions or persistent inflammation
Signs of systemic allergic reaction (rash, breathing difficulty)
Unexpected cardiovascular symptoms during treatment
Any signs of infection at injection sites

References

Cardiac Protection Pilot Study: Thymosin β4 in STEMI Patients (2016)

Humans | EPC pre-treatment with Tβ4 | Single transplantation | Improved cardiac function compared to control

First human study of Thymosin β4 in heart attack patients, demonstrating potential clinical benefits in repairing damaged tissue and improving cardiac function.

View Study →

Phase II Dry Eye Clinical Trial Using Controlled Adverse Environment Model (2015)

Humans | 0.1% topical drops | 28 days | Significant improvement in symptoms and corneal staining

Randomized, double-masked, placebo-controlled study in 72 subjects showing significant positive effects on ocular discomfort and corneal staining with excellent safety profile.

View Study →

Phase I Human Safety Study: Intravenous Thymosin β4 (2010)

Humans | 42-1260 mg IV | Single and multiple doses | Excellent safety profile, no dose-limiting toxicity

First-in-human randomized, placebo-controlled study establishing safety and pharmacokinetics of IV Thymosin β4 administration in healthy volunteers.

View Study →

Neurotrophic Keratopathy Compassionate Use Trial (2010)

Humans | 0.1% topical drops | Up to several months | 6 of 9 subjects achieved complete healing

Physician-sponsored compassionate use trial using RGN-259 formulation showing complete clearing of persistent corneal defects in most subjects.

View Study →

Venous Ulcer European Clinical Trial (2007)

Humans | Topical application | 84 days treatment | Safety and healing enhancement evaluation

Double-blind, placebo-controlled, dose-escalation study across 10 European sites evaluating safety, tolerability, and healing enhancement in venous ulcer patients.

View Study →